Karyopharm Therapeutics Overview
Valuation check: KPTI's ROE is 73.39%, above the Healthcare sector average of 22.76%.
Get informed when a big investor buys or sells
+ Follow73.39%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Karyopharm Therapeutics posts a ROE of 73.39%. That is above the Healthcare sector average of 22.76%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
For Healthcare stocks, a ROE near 22.76% is typical. Karyopharm Therapeutics's 73.39% is higher that level. That is roughly 222.4% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
Karyopharm Therapeutics's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 73.39%; use YoY and peer views to separate noise from signal.
Context for KPTI's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 22.76%), and (3) consistency with growth and profitability. This page covers the first two; Karyopharm Therapeutics's other metric pages and overview cover the third.
Judging Karyopharm Therapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in ROE easier to interpret. Start with 73.39% here, then scan peer and history charts to see if the gap is persistent.
